Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of addiction treatment drugs. The company's lead investigational new drug, AD04, is a genetically targeted serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder (AUD) in patients with alcoholism. It was recently studied in the company’s pivotal Phase 3 clinical trial, ONWARD, aimed at potentially treating AUD in subjects identified with a specific target genotype using the company’s companion diagnostic genetic test (estimated to be about one-third of the AUD population).